Abeona Therapeutics Inc ABEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABEO is a good fit for your portfolio.
News
-
Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
-
Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
Trading Information
- Previous Close Price
- $5.03
- Day Range
- $5.03–5.25
- 52-Week Range
- $2.83–9.01
- Bid/Ask
- $5.00 / $5.28
- Market Cap
- $208.91 Mil
- Volume/Avg
- 241,065 / 637,059
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 34.95
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 84
Comparables
Valuation
|
Metric
|
ABEO
|
EWTX
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.31 | 1.84 |
Price/Sales | 34.95 | — | 3,220.91 |
Price/Cash Flow | — | — | — |
Price/Earnings
ABEO
EWTX
PLRX
Financial Strength
|
Metric
|
ABEO
|
EWTX
|
PLRX
|
|---|---|---|---|
Quick Ratio | 5.43 | 36.49 | 15.95 |
Current Ratio | 5.61 | 37.08 | 16.12 |
Interest Coverage | −61.45 | — | −138.69 |
Quick Ratio
ABEO
EWTX
PLRX
Profitability
|
Metric
|
ABEO
|
EWTX
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −65.61% | −23.18% | −23.39% |
Return on Equity (Normalized) | −364.91% | −24.45% | −25.61% |
Return on Invested Capital (Normalized) | −203.85% | −28.92% | −29.08% |
Return on Assets
ABEO
EWTX
PLRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Fzyyxgsk | Rxqtm | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dygldfyn | Zvgvlm | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vkfnwtx | Kqwvrcv | $118.7 Bil | |||
| Moderna Inc
MRNA
| Nvxqcrmgn | Qdbz | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lgwdkfz | Nmdxbx | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Vzhzxrxx | Nnmf | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Wdhbkqlc | Zjlf | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lpnprzsc | Jdktfb | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Dqhjlnqy | Crrm | $15.0 Bil | |||
| Incyte Corp
INCY
| Sxjjnwx | Cxzrdv | $13.5 Bil |